CompletedPhase 2

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

United States14 participantsStarted 2019-01-14

Plain-language summary

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Suspected prostate cancer * Planned prostate biopsy * Able to provide written consent * Karnofsky performance status of 50 (or ECOG/WHO equivalent) Exclusion Criteria: * Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam * Metallic implants (contraindicated for MRI)

What they're measuring

Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings

Timeframe: Up to approximately 2 hours to complete each scan

Trial details

NCT IDNCT03809078

SponsorAndrei Iagaru

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-08

Results submitted2023-12-01

View on ClinicalTrials.gov More Prostate Cancer trials